Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Ultra High-risk Multiple Myeloma
Conditions: Multiple Myeloma; Primary Plasma Cell Leukemia; Extramedullary Multiple Myeloma Interventions: Drug: Daratumumab; Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Cisplatin; Drug: epirubicin; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Melphalan; Procedure: ASCT; Drug: bortezomib Sponsors: Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: China Health | COVID-19 | Dexamethasone | Hospitals | Leukemia | Myeloma | Research | Revlimid | Velcade